Document:

Exhibit 10.3

 

TAKE-TWO INTERACTIVE SOFTWARE, INC.
 AMENDMENT TO
 PERFORMANCE BASED RESTRICTED STOCK AGREEMENT

 

This Amendment (this “Amendment”) to the Performance Based Restricted Stock Agreement (the “Agreement”), dated as of May 20, 2011, by and between Take-Two Interactive Software, Inc. (the “Company”) and ZelnickMedia Corporation (the “Participant”), is made effective as of December 2, 2014.

 

WHEREAS, the Company and the Participant are parties to the Agreement; and

 

WHEREAS, the Company and the Participant now desire to amend the Agreement in order to amend the vesting date applicable to certain Shares of Restricted Stock granted pursuant to the Agreement.

 

NOW, THEREFORE, in consideration of the covenants and agreements herein contained, the parties hereto hereby agree as follows:

 

1.                                      Capitalized Terms.  Capitalized terms that are not defined in this Amendment shall have the meanings ascribed thereto in the Agreement.

 

2.                                      Amendments to the Agreement.  Annex A attached to the Agreement shall be amended as follows:

 

(a)         All references to “April 1, 2015” shall be replaced with references to “May 15, 2015”.

 

(b)         The Subsequent Vesting Date for purposes of any Shares that remain eligible to vest pursuant to Section B of Annex A shall be May 15, 2015.

 

(c)          The Initial Vesting Date and Subsequent Vesting Date for purposes of any Shares that remain eligible to vest pursuant to the second paragraph of Section C of Annex A shall be May 15, 2015.

 

(d)         Notwithstanding the foregoing amendments, April 1, 2015 shall be the date used to calculate the Measurement Price to determine the Vesting Percentage for purposes of Sections A and B of Annex A.

 

3.                                      Ratification and Confirmation.  Except as specifically amended hereby, the Agreement is hereby ratified and confirmed in all respects and remains in full force and effect, it being the intention of the parties hereto that this Amendment and the Agreement be read, construed and interpreted as one and the same instrument.  In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall control.

 

4.                                      Affirmations of the Participant.  By the Participant’s signature below, the Participant represents to and agrees with the Company that the Participant hereby accepts this Amendment subject to all of the terms and provisions hereof. The Participant has reviewed this

 

1

 

Amendment in its entirety, has had an opportunity to obtain the advice of counsel prior to executing this Amendment and fully understands all of the provisions of this Amendment.

 

5.                                      Governing Law.  This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to principles of conflict of laws.

 

6.                                      Headings.  Section headings are for convenience only and shall not be considered a part of this Amendment.

 

7.                                      Counterparts.  This Amendment may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract.

 

*                                         *                                         *

 

2

 

IN WITNESS WHEREOF, the parties have executed this Amendment to the Agreement as of the date first set forth above.

 

 

	
 
    	
TAKE-TWO INTERACTIVE SOFTWARE, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Daniel Emerson
    
	
 
    	
Name:
    	
Daniel   Emerson
    
	
 
    	
Title:
    	
EVP & GC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
ZELNICKMEDIA CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Karl Slatoff
    
	
 
    	
Name:
    	
Karl   Slatoff
    
	
 
    	
Title
    	
Authorized Signatory
    

 

3Exhibit 10.1

 

SHARE PURCHASE AGREEMENT

 

This Share Purchase
Agreement (this “Agreement”) is dated as of February 3, 2015 by and among Capricor
Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified
on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and, collectively,
the “Purchasers”).

 

RECITALS

 

A.          The
Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule
506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “Commission”) under the Securities Act.

 

B.           Each
Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated
in this Agreement, that aggregate number of shares of common stock of the Company, par value $0.001 per share (the “Common
Stock”), set forth below such Purchaser’s name on the signature page of this Agreement (which aggregate amount
for all Purchasers together shall be 1,658,822 shares of Common Stock and shall be collectively referred to herein as the “Shares”).

 

C.           The
Company has engaged H.C. Wainwright & Co., LLC to act as a placement agent (the “Placement Agent”)
for the offering of the Shares on a “best efforts” basis.

 

D.           Contemporaneously
with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement,
substantially in the form attached hereto as Exhibit A (the “Registration
Rights Agreement”), pursuant to which, among other things, the Company will agree to provide certain registration
rights with respect to the Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable
state securities laws.

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser hereby agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1.          Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have
the meanings indicated in this Section 1.1:

 

“Accredited
Investor Questionnaire” means the Accredited Investor Questionnaire set forth as Exhibit
B hereto.

 

    	 

    	 

    

 

“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened against the Company, any of its properties, or any officer, director or
employee of the Company acting in his or her capacity as an officer, director or employee before or by any federal, state, county,
local or foreign court, arbitrator, governmental or administrative agency, regulatory authority, stock market, stock exchange or
trading facility.

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with such Person; as such terms are used in and construed under Rule 405 under the
Securities Act. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by
the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Board
of Directors” means the board of directors of the Company.

 

“Book Entry
Confirmation” has the meaning set forth in Section 2.2(a)(ii).

 

“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Buy-In”
has the meaning set forth in Section 4.1(f).

 

“Buy-In
Price” has the meaning set forth in Section 4.1(f).

 

“Closing”
means the closing of the purchase and sale of the Shares on the Closing Date pursuant to Section 2.1.

 

“Closing
Bid Price” means, for any security as of any date, (a) the last reported closing bid price per share for such
security on the Principal Trading Market, as reported by Bloomberg Financial Markets, or (b) if the Principal Trading Market
begins to operate on an extended hours basis and does not designate the closing bid price then the last bid price of such security
prior to 4:00 p.m., New York City time, as reported by Bloomberg Financial Markets, or (c) if the foregoing do not apply,
the last closing price of such security in the over-the-counter market on the electronic bulletin board for such security as reported
by Bloomberg Financial Markets, or (d) if no closing bid price is reported for such security by Bloomberg Financial Markets,
the average of the bid prices of any market makers for such security as reported on OTC Pink (also known as the “pink sheets”)
by the OTCMarkets. If the Closing Bid Price cannot be calculated for a security on a particular date on any of the foregoing bases,
the Closing Bid Price of such security on such date shall be the fair market value as mutually determined by the Company and the
holder of such security. If the Company and such holder are unable to agree upon the fair market value of such security, then the
Board of Directors shall use its good faith judgment to determine the fair market value. The Board of Directors’ determination
shall be binding on all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock
dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

    	2

    	 

    

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all of the conditions set forth in Sections 2.2, 5.1 and 5.2 hereof
are satisfied or waived, as the case may be, or such other date as the parties may agree.

 

“Commission”
has the meaning set forth in the Recitals.

 

“Common
Stock” has the meaning set forth in the Recitals, and also includes any other class of securities into which the
Common Stock may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at
any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock, or other securities
that entitle the holder to receive, directly or indirectly, Common Stock.

 

“Company”
has the meaning set forth in the Preamble.

 

“Company
Counsel” means Paul Hastings LLP, with offices located at 1117 S. California Avenue, Palo Alto, California 94304.

 

“Company
Deliverables” has the meaning set forth in Section 2.2(a).

 

“Company’s
Knowledge” means, with respect to any statement made to the Company’s Knowledge, that the statement is based
upon the actual knowledge of Linda Marbán, Ph.D., Chief Executive Officer of the Company.

 

“Deadline
Date” has the meaning set forth in Section 4.1(f).

 

“Disclosure
Materials” has the meaning set forth in Section 3.1(h).

 

“Disclosure
Schedules” has the meaning set forth in Section 3.1.

 

“DTC”
has the meaning set forth in Section 4.1(c).

 

“Effective
Date” means the date on which the Initial Registration Statement (as defined in the Registration Rights Agreement)
required by Section 2(a) of the Registration Rights Agreement is first declared effective by the Commission.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder.

 

    	3

    	 

    

 

“Fund”
has the meaning set forth in Section 3.2(k).

 

“GAAP”
means U.S. generally accepted accounting principles, as applied by the Company.

 

“Indemnified
Person” has the meaning set forth in Section 4.7.

 

“Intellectual
Property Rights” has the meaning set forth in Section 3.1(o).

 

“Irrevocable
Transfer Agent Instructions” has the meaning set forth in Section 4.1(d).

 

“Lien”
means any lien, charge, deed of trust, claim, encumbrance, security interest, priority, right or preferential arrangement of any
kind or nature whatsoever (excluding preferred stock and equity related preferences) or other restrictions of any kind.

 

“Material
Adverse Effect” means a material adverse effect on the results of operations, assets (including intangible assets),
liabilities, properties, prospects, business or financial condition of the Company and the Subsidiaries, taken as a whole, except
that any of the following, either alone or in combination, shall not be deemed a Material Adverse Effect: (a) effects caused
by changes or circumstances affecting general market conditions in the U.S. economy or which are generally applicable to the industry
in which the Company operates, provided that such effects are not borne disproportionately by the Company; (b) effects caused
by earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of
any such hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof; (c) effects resulting
from or relating to the announcement or disclosure of the sale of the Shares or other transactions contemplated by this Agreement;
(d) effects caused by a failure to meet projections; or (e) effects caused by any event, occurrence or condition resulting
directly from or directly relating to the taking of any action as required in accordance with this Agreement.

 

“Material
Contract” means any contract of the Company that has been filed or was required to have been filed as an exhibit
to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.

 

“Outside
Date” means the 10th Business Day following the date of this Agreement.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Placement
Agent” has the meaning set forth in the Recitals.

 

“Press
Release” has the meaning set forth in Section 4.4.

 

    	4

    	 

    

 

“Principal
Trading Market” means the Trading Market on which the Common Stock is primarily listed and quoted for trading, which,
as of the date of this Agreement and the Closing Date, shall be the OTCQB Market.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Purchase
Price” means $4.25 for each share of Common Stock to be purchased hereunder, subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement and before the Closing Date.

 

“Purchaser”
or “Purchasers” has the meaning set forth in the Recitals.

 

“Purchaser
Deliverables” has the meaning set forth in Section 2.2(b).

 

“Purchaser
Party” has the meaning set forth in Section 4.7.

 

“Registration
Rights Agreement” has the meaning set forth in the Recitals.

 

“Registration
Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement
and covering the resale by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement).

 

“Regulation
D” has the meaning set forth in the Recitals.

 

“Required
Approvals” has the meaning set forth in Section 3.1(e).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.

 

“SEC Reports”
has the meaning set forth in Section 3.1(h).

 

“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vi).

 

“Securities
Act” has the meaning set forth in the Recitals.

 

“Shares”
has the meaning set forth in the Recitals.

 

“Short
Sales” has the meaning set forth in Section 3.2(k).

 

“Subscription
Amount” means, with respect to each Purchaser, the aggregate amount to be paid for the Shares purchased hereunder
as indicated on such Purchaser’s signature page to this Agreement next to the heading “Aggregate Purchase Price (Subscription
Amount)” in United States dollars and in immediately available funds.

 

    	5

    	 

    

 

“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, include any corporation,
partnership, limited liability company, joint venture or other legal entity, formed or acquired by the Company after the date hereof, provided
that the Company owns, directly or indirectly, more than 50% of the stock or other voting equity interests of such corporation
or other legal entity.

 

“Trading
Day” means (a) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market
(other than the OTCMarkets), or (b) if the Common Stock is not listed on a Trading Market (other than the OTCMarkets), a day
on which the Common Stock is traded in the over-the-counter market, as reported by the OTCMarkets (or any similar organization
or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not
listed or quoted as set forth in (a) or (b) hereof, then Trading Day shall mean a Business Day.

 

“Trading
Market” means whichever of the NYSE MKT LLC, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ
Capital Market or the OTCMarkets on which the Common Stock is listed or quoted for trading on the date in question.

 

“Transaction
Documents” means this Agreement, the schedules and exhibits attached hereto, the Registration Rights Agreement, the
Irrevocable Transfer Agent Instructions, the Accredited Investor Questionnaires and any other documents or agreements explicitly
contemplated hereunder.

 

“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the current transfer agent of the Company, with a
mailing address of 6201 15th Avenue, Brooklyn, NY 11219, and a telephone number of (718) 921-8200, or any successor transfer agent
for the Company.

 

ARTICLE II

PURCHASE AND SALE

 

2.1.          
Closing.

 

(a)          Amount.
Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Purchaser,
and each Purchaser shall, severally and not jointly, purchase from the Company, that number of Shares equal to the quotient
resulting from dividing (i) the Subscription Amount for such Purchaser by (ii) the Purchase Price, rounded down to the nearest
whole Share.

 

(b)          Closing.
The Closing of the purchase and sale of the Shares shall take place at the offices of Paul Hastings LLP, located at 1117 S. California
Avenue, Palo Alto, California 94304 on the Closing Date or at such other location(s) or remotely by facsimile transmission or other
electronic means as the parties may mutually agree.

 

    	6

    	 

    

 

(c)          Form
of Payment. Except as may otherwise be agreed to among the Company and one or more of the Purchasers, on or prior to the Business
Day immediately prior to the Closing Date, each Purchaser shall wire its Subscription Amount, in United States dollars and in immediately
available funds, in accordance with the wire instructions provided by the Company to such Purchaser prior to the Closing. Promptly
following the Closing Date, but not later than five business days thereafter, upon receipt of the Subscription Amounts, the Company
shall (i) pay to the Placement Agent its respective fees, (ii) reimburse the Placement Agent for any reimbursable expenses
payable to the Placement Agent within 30 days after receipt of an itemized invoice therefor and copies of receipts or other substantiation
of such expenses and charges, and (iii) irrevocably instruct the Transfer Agent to deliver to each Purchaser one or more Book
Entry Confirmations (as defined below), free and clear of all restrictive and other legends (except as expressly provided in Section
4.1(b)), evidencing the number of Shares such Purchaser is purchasing as set forth on such Purchaser’s signature page
to this Agreement next to the heading “Number of Shares to be Acquired”, within three Trading Days after the Closing
Date.

 

2.2.          
Closing Deliveries.

 

(a)          On
or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser (except as noted), the following
(the “Company Deliverables”):

 

(i)          this
Agreement, duly executed by the Company;

 

(ii)         facsimile
copies of one or more Book Entry Confirmations, free and clear of all restrictive and other legends (except as provided in Section
4.1(b)), evidencing the Shares subscribed for by such Purchaser, as calculated in accordance with Section 2.1(a), registered
in the name of such Purchaser as set forth on the Accredited Investor Questionnaire included as Exhibit
B hereto (the “Book Entry Confirmations”);

 

(iii)        a
legal opinion of Company Counsel, dated as of the Closing Date and in substantially the form attached hereto as Exhibit
D, executed by such counsel and addressed to the Purchasers;

 

(iv)        the
Registration Rights Agreement, duly executed by the Company;

 

(v)         duly
executed Irrevocable Transfer Agent Instructions acknowledged in writing by the Transfer Agent;

 

(vi)        a
certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing
Date, evidencing (i) the incorporation and good standing of the Company issued by the Secretary of State of the State of Delaware
as of a date within five days of the Closing Date, (ii) the Company’s qualification as a foreign corporation and good standing
issued by the Secretary of State of the State of California as of a date within 15 days of the Closing Date, and (iii) a certified
copy of the certificate of incorporation of the Company, as certified by the Secretary of State of the State of Delaware, as of
a date within 15 days of the Closing Date, in substantially the form attached hereto as Exhibit
E; and

 

    	7

    	 

    

 

(vii)       the
Compliance Certificate referred to in Section 5.1(h).

 

(b)          On
or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following, with respect to such
Purchaser (the “Purchaser Deliverables”):

 

(i)          this
Agreement, duly executed by such Purchaser;

 

(ii)         its
Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth below such Purchaser’s
name on the applicable signature page hereto under the heading “Aggregate Purchase Price (Subscription Amount)”;

 

(iii)        the
Registration Rights Agreement, duly executed by such Purchaser; and

 

(iv)        a
fully completed and duly executed Accredited Investor Questionnaire, satisfactory to the Company, in the form attached hereto as Exhibit
B.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

3.1.          Representations
and Warranties of the Company. Except as (i) set forth in the schedules delivered herewith (the “Disclosure
Schedules”), which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein
to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules or other representations relating
to the subject matter of such disclosures, or (ii) specifically disclosed in the SEC Reports, which shall be deemed to qualify
any representation made herein that specifically references such SEC Reports, the Company hereby represents and warrants as of
the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall
be made as of such date), to each of the Purchasers and to the Placement Agent, as follows:

 

(a)          Subsidiaries.
The Company has no direct or indirect subsidiaries other than those set forth on Schedule 3.1(a) to the Disclosure
Schedule. Except as set forth on Schedule 3.1(a) to the Disclosure Schedule, the Company owns, directly or indirectly,
all of the capital stock or comparable equity interests of each Subsidiary free and clear of any and all Liens, and all the issued
and outstanding shares of capital stock or comparable equity interests of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

 

(b)          Organization
and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the
requisite corporate power and authority to own or lease and use its properties and assets and to carry on its business as currently
conducted. Except as set forth on Schedule 3.1(b) to the Disclosure Schedule, neither the Company nor any Subsidiary is
in violation or default of any of the provisions of its respective certificate of incorporation or bylaws or other organizational
documents. The Company and each of its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or
reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been instituted, is pending, or, to the Company’s
Knowledge, has been threatened in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.

 

    	8

    	 

    

 

(c)          Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and
thereunder. The Company’s execution and delivery of each of the Transaction Documents to which it is a party and the consummation
by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Shares)
have been duly authorized by all necessary corporate action on the part of the Company, and no further corporate action is required
by the Company, its Board of Directors or its stockholders in connection therewith other than in connection with the Required Approvals.
Each of the Transaction Documents to which it is a party has been (or upon delivery will have been) duly executed by the Company
and is, or when delivered in accordance with the terms hereof, will constitute, the legal, valid and binding obligation of the
Company enforceable against the Company in accordance with its terms, except (i) as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally
the enforcement of, creditors’ rights and remedies or by other equitable principles of general application, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, and (iii) insofar
as indemnification and contribution provisions may be limited by applicable law.

 

(d)          No
Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance of
the Shares) do not and will not (i) conflict with or violate any provisions of the Company’s or any Subsidiary’s
certificate of incorporation or bylaws or otherwise result in a violation of the organizational documents of the Company, (ii) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would result in a default) under, result in
the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary or give to others any rights of
termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract,
or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject
(including federal and state securities laws and regulations and the rules and regulations, assuming the correctness of the representations
and warranties made by the Purchasers herein, of any self-regulatory organization to which the Company or its securities are subject,
including all applicable Trading Markets), or by which any property or asset of the Company is bound or affected, except in the
case of clauses (ii) and (iii) such as would not, individually or in the aggregate, have or reasonably be expected to
result in a Material Adverse Effect or a material adverse effect on the legality, validity or enforceability of any Transaction
Document or the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document.

 

    	9

    	 

    

 

(e)          Filings,
Consents and Approvals. Except as set forth on Schedule 3.1(e) to the Disclosure Schedule, neither the Company nor any
of its Subsidiaries is required to obtain any consent, waiver, approval, authorization or order of, give any notice to, or make
any filing or registration with, any court or other federal, state, local or other governmental authority, holder of outstanding
securities of the Company or other Person in connection with the execution, delivery and performance by the Company of the Transaction
Documents (including the issuance of the Shares), other than (i) the filing with the Commission of one or more Registration
Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings required by applicable state
securities laws, (iii) the filing of a Notice of Sale of Securities on Form D with the Commission under Regulation D of the
Securities Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market for the issuance
and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the time and manner
required thereby, (v) the filings required in accordance with Section 4.4, and (vi) those that have been made
or obtained prior to the date of this Agreement (collectively, the “Required Approvals”).

 

(f)          Issuance
of the Shares. The Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction
Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions
on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive
or similar rights of stockholders. Assuming the accuracy of the representations and warranties of the Purchasers in this Agreement,
the Shares will be issued in compliance with all applicable federal and state securities laws.

 

(g)          Capitalization.
The capitalization of the Company is as described in its most recently filed SEC Report on Form 10-Q, except for issuances pursuant
to this Agreement, stock option exercises, issuances pursuant to equity incentive plans or exercises of warrants. The Company has
not issued any capital stock since the date of its most recently filed SEC Report other than to reflect stock option and warrant
exercises that do not, individually or in the aggregate, have a material effect on the issued and outstanding capital stock, options
and other securities of the Company. No Person has any right of first refusal, preemptive right, right of participation, or any
similar right to participate in the transactions contemplated by the Transaction Documents that have not been effectively waived
as of the Closing Date. Except as set forth on Schedule 3.1(g), or as a result of the purchase and sale of the Shares,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to
subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. Except as set
forth on Schedule 3.1(g), the issuance and sale of the Shares will not obligate the Company to issue shares of Common
Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities
to adjust the exercise, conversion, exchange or reset price under any of such securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Shares. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the Company’s Knowledge, between or among any of the Company’s stockholders.

 

    	10

    	 

    

 

(h)          SEC
Reports; Disclosure Materials. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the “SEC Reports”, and the SEC Reports, together with the Disclosure Schedules, being collectively
referred to as the “Disclosure Materials”) on a timely basis or has received a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any such extension, except where the failure to file
on a timely basis would not have or reasonably be expected to result in a Material Adverse Effect and would not have or reasonably
be expected to result in any limitation or prohibition on the Company’s ability to register the Shares for resale on Form
S-1 or any Purchaser’s ability to use Rule 144 to resell any Shares. As of their respective filing dates, or to the extent
corrected by a subsequent amendment, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC Reports, when
filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company
has never been an issuer subject to Rule 144(i) under the Securities Act. Except as set forth on Schedule 3.1(h) to
the Disclosure Schedule, each of the Material Contracts to which the Company or any Subsidiary is a party or to which the property
or assets of the Company or any of its Subsidiaries are subject has been filed (or incorporated by reference) as an exhibit to
the SEC Reports, other than the Transaction Documents.

 

(i)          Financial
Statements. The consolidated financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the
time of filing (or to the extent corrected by a subsequent amendment). Such consolidated financial statements have been prepared
in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such
consolidated financial statements or the consolidated notes thereto and except that unaudited consolidated financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries taken as a whole as of and for the dates thereof and the results of operations and cash flows
for the periods then ended, subject, in the case of unaudited consolidated statements, to normal, immaterial year-end audit adjustments.

 

    	11

    	 

    

 

(j)          Material
Changes. Since the date of the latest financial statements included within the SEC Reports, except as specifically disclosed
in a subsequent SEC Report filed prior to the date hereof and except as set forth on Schedule 3.1(j) to the Disclosure Schedule,
(i) there have been no events, occurrences or developments that have had or would reasonably be expected to have, either individually
or in the aggregate, a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or
otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past
practice and (B) liabilities not required to be reflected in the Company’s consolidated financial statements pursuant to
GAAP or required to be disclosed in filings made with the Commission, (iii) the Company has not altered materially its method
of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not declared or made
any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the
Company), and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except Common Stock
issued pursuant to existing Company stock option or stock purchase plans or executive and director compensation arrangements disclosed
in the SEC Reports. Except as set forth on Schedule 3.1(j) to the Disclosure Schedule and except for the issuance
of the Shares contemplated by this Agreement, no event, liability or development has occurred or exists with respect to the Company
or its Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made that has not been publicly disclosed at
least one Trading Day prior to the date that this representation is made.

 

(k)          Litigation.
There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Shares, or (ii) would, if there were an unfavorable decision, individually or in the aggregate, have or reasonably
be expected to result in a Material Adverse Effect. During the past five years, neither the Company nor any Subsidiary, nor to
the Company’s Knowledge any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s
Knowledge there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. During the past five years, the Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities Act.

 

(l)          Employment
Matters. No material labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of the employees
of the Company which would have or would reasonably be expected to result in a Material Adverse Effect. None of the Company’s
or any Subsidiary’s employees is a member of a labor union that relates to such employee’s relationship with the Company,
and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. No executive officer of the
Company (as defined in Rule 405 of the Securities Act) has notified the Company or any of its Subsidiaries that such officer intends
to leave the Company or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such
Subsidiary. The Company is in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment
and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance
would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

    	12

    	 

    

 

(m)          Compliance.
Except as set forth on Schedule 3.1(m) to the Disclosure Schedule, neither the Company nor any of its Subsidiaries (i) is
in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both,
would result in a default by the Company or any of its Subsidiaries under), nor has the Company or any of its Subsidiaries received
written notice of a claim that it is in default under or that it is in violation of, any Material Contract (whether or not such
default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body having
jurisdiction over the Company or any of its Subsidiaries or their properties or assets, or (iii) is in violation of, or in
receipt of written notice that it is in violation of, any statute, rule or regulation of any governmental authority applicable
to the Company or any of its Subsidiaries, except in the case of each of clauses (i), (ii) and (iii), as would not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.

 

(n)          Title
to Assets. The Company and each of its Subsidiaries has good and marketable title to all tangible personal property owned by
it that is material to its respective businesses, in each case free and clear of all Liens except such as do not materially affect
the value of such property and do not interfere with the use made and proposed to be made of such property by the Company. Except
as set forth on Schedule 3.1(n) to the Disclosure Schedule, any real property and facilities held under lease by the Company
or any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material
and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries.

 

(o)          Patents
and Trademarks. To the Company’s Knowledge, the Company and each of its Subsidiaries owns, possesses, licenses or has
other rights to use, all patents, patent applications, trade and service marks, trade and service mark applications and registrations,
trade names, trade secrets, inventions, copyrights, licenses, technology, know-how and other intellectual property rights and similar
rights necessary or material for use in connection with its respective businesses as described in the SEC Reports and which the
failure to so have would have or reasonably be expected to result in a Material Adverse Effect (collectively, the “Intellectual
Property Rights”). Except as set forth on Schedule 3.1(o) to the Disclosure Schedule, there is no pending
or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by any Person that the Company’s or any
Subsidiary’s business as now conducted infringes or otherwise violates any patent, trademark, copyright, trade secret or
other proprietary rights of another. To the Company’s Knowledge, there is no existing infringement by another Person of any
of the Intellectual Property Rights that would have or would reasonably be expected to result in a Material Adverse Effect. Except
as set forth on Schedule 3.1(o) to the Disclosure Schedule, there is no pending or, to the Company’s Knowledge,
threatened action, suit, proceeding or claim by another Person challenging the Company’s or any Subsidiary’s rights
in or to any material Intellectual Property Rights, or challenging inventorship, validity or scope of any such Intellectual Property
Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all of its and
its Subsidiaries’ Intellectual Property Rights. None of the technology employed by the Company or any of its Subsidiaries
has been obtained or is being used by the Company or any Subsidiary in violation of any contractual obligation binding on the Company
or any Subsidiary or, to the Company’s Knowledge, any of its or its Subsidiaries’ officers, directors or employees
or otherwise in violation of the rights of any Person, which violations would have or would reasonably be expected to have a Material
Adverse Effect.

 

    	13

    	 

    

 

(p)          Insurance.
The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as the Company believes to be prudent and customary in the businesses and locations in which the Company
and the Subsidiaries are engaged. Except as set forth on Schedule 3.1(p) to the Disclosure Schedule, none of the Company
or any of its Subsidiaries has received any written notice of cancellation of any such insurance, nor, to the Company’s Knowledge,
will it or any Subsidiary be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business without a material increase in cost.

 

(q)          Transactions
with Affiliates and Employees. Except as set forth in the SEC Reports, none of the executive officers or directors of the Company
and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company
(other than for services as employees, officers and directors) that would be required to be disclosed pursuant to Item 404 of Regulation
S-K promulgated under the Securities Act.

 

(r)          Internal
Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability
accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets and liabilities is compared with the existing
assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences.

 

(s)          Certain
Fees. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim
against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of the Company, other than the Placement Agent with respect to the offer and sale
of the Shares (which fees are being paid by the Company). The Purchasers shall have no obligation with respect to any fees or with
respect to any claim made by or on behalf of other Persons for fees of a type contemplated in this Section 3.1(s) pursuant
to any agreement to which the Company is a party that may be due in connection with the transactions contemplated by the Transaction
Documents.

 

    	14

    	 

    

 

(t)          Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
and the accuracy of the information disclosed in the Accredited Investor Questionnaires provided by the Purchasers, no registration
under the Securities Act is required for the offer and sale of the Shares by the Company to the Purchasers under the Transaction
Documents. The issuance and sale of the Shares hereunder does not contravene the rules and regulations of the Principal Trading
Market.

 

(u)          Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not
be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

(v)         Registration
Rights. Other than each of the Purchasers pursuant to the Registration Rights Agreement and the holders of warrants and other
investors of the Company listed on Schedule 3.1(v) attached hereto, no Person has any right to cause the Company to effect
the registration under the Securities Act of any securities of the Company.

 

(w)          Registration
of Common Stock. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act, nor
has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not,
in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is listed
or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market.
The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all
listing and maintenance requirements of the Principal Trading Market on the date hereof.

 

(x)          Application
of Takeover Protections; Rights Agreements. The Company and the Board of Directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of its state
of incorporation that is or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation,
the Company’s issuance of the Shares and the Purchasers’ ownership of the Shares.

 

(y)          Disclosure.
All disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company, its business and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects and does
not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that
no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than
those specifically set forth in Section 3.2 or in the Accredited Investor Questionnaires provided by the Purchasers.

 

    	15

    	 

    

 

(z)          Tax
Matters. The Company and each of its Subsidiaries (i) have paid all taxes and other governmental assessments and charges
that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested
in good faith, with respect to which adequate reserves have been set aside on the books of the Company, and (ii) have set
aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such
returns, reports or declarations apply, except, in the case of clause (i) above, where the failure to so pay or file any such
tax, assessment, charge or return would not have or reasonably be expected to result in a Material Adverse Effect.

 

(aa)         Off-Balance
Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company, any Subsidiary and an
unconsolidated or other off-balance sheet entity that is required to be disclosed by the Company in the SEC Reports and is not
so disclosed and would have or reasonably be expected to result in a Material Adverse Effect.

 

(bb)         Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any agent or other
person acting on behalf of the Company or any of its Subsidiaries, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made
any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or
campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or
made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any
material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

(cc)         Acknowledgment
Regarding Purchasers’ Purchase of Shares. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice
given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the
transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Shares. The Company further represents
to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

(dd)         No
Additional Agreements. The Company does not have any agreement or understanding with any Purchaser with respect to the transactions
contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

    	16

    	 

    

 

(ee)         No
Disqualification Events.  With respect to the Shares to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated
issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner
of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each,
an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent
applicable, with its disclosure obligations under Rule 506(e).

 

3.2.            Representations
and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as
of the date hereof and as of the Closing Date to the Company and the Placement Agent as follows:

 

(a)          Organization;
Authority. If Purchaser is not a natural person, such Purchaser is an entity duly organized, validly existing and in good standing
under the laws of the jurisdiction of its organization with the requisite corporate, limited liability company or partnership power
and authority to enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by such Purchaser and, if Purchaser
is not a natural person, the performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized
by all necessary corporate, partnership, limited liability company or other applicable like action, on the part of such Purchaser.
Each Transaction Document to which such Purchaser is a party has been duly executed by such Purchaser, and when delivered by such
Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies
or by other equitable principles of general application.

 

(b)          No
Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the Registration Rights Agreement
and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Purchaser,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to
perform its obligations hereunder.

 

    	17

    	 

    

 

(c)          Investment
Intent. Such Purchaser understands that the Shares are “restricted securities” and have not been registered under
the Securities Act or any applicable state securities law and is acquiring the Shares as principal for its own account and not
with a view to, or for distributing or reselling such Shares or any part thereof in violation of the Securities Act or any applicable
state securities laws, provided, however, that by making the representations herein, such Purchaser does
not agree to hold any of the Shares for any minimum period of time and reserves the right, subject to the provisions of this Agreement
and the Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such Shares pursuant to
an effective registration statement under the Securities Act or under an exemption from such registration and in compliance with
applicable federal and state securities laws. Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.
Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute
or effect any distribution of any of the Shares (or any securities which are derivatives thereof) to or through any person or entity;
such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that would
require it to be so registered as a broker-dealer.

 

(d)          Purchaser
Status. At the time such Purchaser was offered the Shares, it was, and at the date hereof it is, and on the Closing Date it
will be, an “accredited investor” as defined in Rule 501(a) under the Securities Act.

 

(e)          General
Solicitation. Such Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication
regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general advertisement.

 

(f)          Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Shares and, at the present time, is able to afford a complete loss of such investment.

 

(g)          Access
to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the Disclosure Materials and has been afforded (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Shares and the merits and risks of investing in the Shares, (ii) access to information about the Company
and its Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment, and (iii) the opportunity to obtain such additional information that the
Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision
with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser
or its representatives or counsel shall modify, amend or affect such Purchaser’s right to rely on the truth, accuracy and
completeness of the Company’s representations and warranties contained in the Transaction Documents. Such Purchaser understands
that its investment in the Shares involves a high degree of risk. Such Purchaser has sought such accounting, legal and tax advice
as it has considered necessary to make an informed decision with respect to its acquisition of the Shares.

 

    	18

    	 

    

 

(h)          Brokers
and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of such Purchaser.

 

(i)          Independent
Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Shares pursuant to the
Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s business
and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other materials
presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Shares constitutes legal, tax
or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Shares. Such Purchaser understands that the Placement Agent has
acted solely as the agent of the Company in this placement of the Shares and such Purchaser has not relied on the business or legal
advice of the Placement Agent or any of its agents, counsel or Affiliates in making its investment decision hereunder, and confirms
that none of such Persons has made any representations or warranties to such Purchaser in connection with the transactions contemplated
by the Transaction Documents. Neither the Placement Agent nor any Affiliate of the Placement Agent has made or makes any representation
as to the Company or the quality of the Shares.  In connection with the issuance of the Shares to such Purchaser, neither
the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.

 

(j)          Reliance
on Exemptions. Such Purchaser understands that the Shares are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements
and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility
of such Purchaser to acquire the Shares.

 

    	19

    	 

    

 

(k)          Certain
Trading Activities. Such Purchaser has not directly or indirectly engaged in any Short Sales involving the Company’s
securities since the time that it was first contacted by the Company with respect to the transactions contemplated hereby. “Short
Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation
SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short
sales, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-US broker
dealers or foreign regulated brokers. Notwithstanding the foregoing, in the case of a Purchaser that is or is part of a multi-managed
investment vehicle (a “Fund”) whereby separate portfolio managers manage separate portions of such Fund’s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Fund’s assets, the representation set forth above shall solely apply with respect to the portion of
assets of such Purchaser managed by the portfolio manager that made the investment decision to purchase the Shares covered by this
Agreement. Such Purchaser hereby covenants and agrees not to engage, directly or indirectly, in any transactions in the securities
of the Company or involving the Company’s securities during the period from the date hereof until such time as (i) the
transactions contemplated by this Agreement are first publicly announced as described in Section 4.4 or (ii) this
Agreement is terminated in full pursuant to Section 6.17. Notwithstanding the foregoing, for avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of
the availability of, or securing of, available shares to borrow in order to effect short sales or similar transactions in the future.

 

(l)          No
Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment in
the Shares nor have such authorities passed upon or endorsed the merits of the offering of the Shares.

 

(m)          Residency.
Such Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the Shares was
made (if an entity) are located at the address immediately below such Purchaser’s name on its signature page hereto.

 

(n)          Accuracy
of Accredited Investor Questionnaire. The Accredited Investor Questionnaire delivered by such Purchaser in connection with
this Agreement is complete and accurate in all respects as of the date of this Agreement and will be correct as of the Closing
Date.

 

(o)          Regulation
M Compliance. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to
sales of Common Stock and other activities with respect to the Common Stock by the Purchasers, and agrees to comply with such rules.

 

The Company and each
of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction
Documents.

 

    	20

    	 

    

 

ARTICLE IV

OTHER AGREEMENTS OF THE PARTIES

 

4.1.          Transfer
Restrictions.

 

(a)          Compliance
with Laws. Notwithstanding any other provision of this Article IV, each Purchaser, severally but not jointly, covenants
that the Shares may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements
of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer
of the Shares other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant
to Rule 144 (provided that such Purchaser provides the Company with reasonable assurances (in the form of seller and,
if applicable, broker representation letters) that the Shares may be sold pursuant to such rule), or (iv) in connection with
a bona fide pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to
the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of
which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of
such transferred Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be
bound by the terms of this Agreement and the Registration Rights Agreement by executing a joinder agreement to each of the same,
and shall have the rights of a Purchaser under this Agreement and the Registration Rights Agreement with respect to such transferred
Shares upon such execution.

 

(b)          Legends.
Book Entry Confirmations evidencing the Shares shall bear any legend as required by the “blue sky” laws of any state
and a restrictive legend in substantially the following form, until such time as they are not required under Section 4.1(c):

 

THESE SHARES HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES
LAWS. THE SHARES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SHARES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER
SAID ACT.

 

The Company acknowledges
and agrees that a Purchaser may from time to time pledge, and/or grant a security interest in, some or all of the legended Shares
in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona fide margin loan.
Such a pledge would not be subject to approval or consent of the Company and no legal opinion of legal counsel to the pledgee,
secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection
with a subsequent transfer or foreclosure following default by such Purchaser transferee of the pledge. No notice shall be required
of such pledge, but such Purchaser’s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure
of such legended Shares. Each Purchaser acknowledges that the Company shall not be responsible for (i) any pledges relating
to, or the grant of any security interest in, any of the Shares or for any agreement, understanding or arrangement between any
Purchaser and its pledgee or secured party, or (ii) any violations of applicable securities laws that may result from the
sale of pledged shares as a result of the Purchaser holding material non-public information at the time of such sale. At the appropriate
Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of
Shares may reasonably request in connection with a pledge or transfer of the Shares, including the preparation and filing of any
required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities
Act to appropriately amend the list of selling stockholders thereunder. Each Purchaser acknowledges and agrees that, except as
otherwise provided in Section 4.1(c), any Shares subject to a pledge or security interest as contemplated by this Section
4.1(b) shall continue to bear the legend set forth in this Section 4.1(b) and be subject to the restrictions
on transfer set forth in Section 4.1(a).

 

    	21

    	 

    

 

(c)          Removal
of Legends. The legend set forth in Section 4.1(b) above shall be removed and the Company shall issue a book
entry confirmation without such legend or any other legend to the holder of the applicable Shares upon which it is stamped or issue
to such holder by electronic delivery at the applicable balance account at the Depository Trust Company (“DTC”),
if (i) such Shares are registered for resale under the Securities Act (provided that, if a Purchaser is selling pursuant
to an effective Registration Statement, then such Purchaser agrees to only sell such Shares during such time that such Registration
Statement is effective and not withdrawn or suspended, and only as permitted by such Registration Statement), (ii) such Shares
are sold or transferred pursuant to Rule 144 (if the transferor is not an Affiliate of the Company), or (iii) such Shares
are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to such securities and without volume or manner-of-sale restrictions. Following the earlier of (A) the
Effective Date or (B) Rule 144 becoming available for the resale of such Shares, without the requirement for the Company to
be in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale
restrictions, the Company shall deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall reissue a
book entry confirmation representing the applicable Shares without legend upon receipt by the Transfer Agent of the legended book
entry confirmation for such Shares. Any fees with respect to the Transfer Agent and all DTC fees associated with the removal of
such legend shall be borne by the Company. Following the Effective Date, or at such earlier time as a legend is no longer required
for certain Shares (in which case a Purchaser shall also be required to provide reasonable assurances (in the form of seller and,
if applicable, broker representation letters) that a legend is no longer required), the Company will, no later than three Trading
Days following the delivery by a Purchaser to the Company or the Transfer Agent (with notice to the Company) of a legended book
entry confirmation representing Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary
to effect the reissuance and/or transfer thereof) and an opinion of counsel to the extent required by Section 4.1(a),
deliver or cause to be delivered to the transferee of such Purchaser or such Purchaser, as applicable, a book entry confirmation
representing such Shares that is free from all restrictive and other legends. The Company may not make any notation on its records
or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4.1(c) other
than to comply with applicable law. Book entry confirmations for Shares subject to legend removal hereunder may be transmitted
by the Transfer Agent to a Purchaser by crediting the account of such Purchaser’s prime broker with DTC as directed by such
Purchaser.

 

    	22

    	 

    

 

(d)          Irrevocable
Transfer Agent Instructions. The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent transfer
agent, in substantially the form of Exhibit C attached hereto (the
“Irrevocable Transfer Agent Instructions”). The Company represents and warrants that no instruction other
than the Irrevocable Transfer Agent Instructions referred to in this Section 4.1(d) (or instructions that are
consistent therewith) will be given by the Company to the Transfer Agent in connection with this Agreement, and that the Shares
shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement
and the other Transaction Documents and applicable law. The Company acknowledges that a breach by it of its obligations under this Section
4.1(d) will cause irreparable harm to a Purchaser. Accordingly, the Company acknowledges that the remedy at law for a
breach of its obligations under this Section 4.1(d) will be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Section 4.1(d), that a Purchaser shall be entitled, in addition
to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer,
without the necessity of showing economic loss and without any bond or other security being required.

 

(e)          Acknowledgement.
Each Purchaser, severally but not jointly, acknowledges its primary responsibilities under the Securities Act and accordingly will
not sell or otherwise transfer the Shares or any interest therein without complying with the requirements of the Securities Act
and applicable law. While the Registration Statement remains effective, each Purchaser hereunder may sell the Shares in accordance
with the plan of distribution contained in the Registration Statement and if it does so it will comply therewith and with the related
prospectus delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the
other Purchasers, agrees that if it is notified by the Company in writing at any time that the Registration Statement registering
the resale of the Shares is not effective or that the prospectus included in such Registration Statement no longer complies with
the requirements of Section 10 of the Securities Act, such Purchaser will refrain from selling such Shares until such time as the
Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant with Section
10 of the Securities Act, unless such Purchaser is able to, and does, sell such Shares pursuant to an available exemption from
the registration requirements of Section 5 of the Securities Act. Both the Company and its Transfer Agent, and their respective
directors, officers, employees and agents, may rely on this Section 4.1(e) and each Purchaser, severally but not
jointly, with the other Purchasers will indemnify and hold harmless each of such persons from any breaches or violations of this Section
4.1(e).

 

(f)          Buy-In.
If the Company shall fail for any reason or for no reason to issue to a Purchaser unlegended book entry confirmations within three
Trading Days after receipt of all documents necessary for the removal of the legend set forth above (the “Deadline
Date”), then, in addition to all other remedies available to such Purchaser, if on or after the Trading Day immediately
following such three Trading Day period, such Purchaser is required to purchase (in an open market transaction or otherwise) shares
of Common Stock to deliver in satisfaction of a sale by the holder of shares of Common Stock that such Purchaser anticipated receiving
from the Company without any restrictive legend (a “Buy-In”), then the Company shall, within three Trading
Days after such Purchaser’s request and in the Company’s sole discretion, either (i) pay cash to such Purchaser
in an amount equal to such Purchaser’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased (the “Buy-In Price”), at which point the shares of Common Stock held by such Purchaser
equal to the number of shares of Common Stock so purchased shall be forfeited to the Company and the Company’s obligation
to deliver such book entry confirmation (and to issue such shares of Common Stock) shall terminate, or (ii) promptly honor
its obligation to deliver to such Purchaser a book entry confirmation representing such shares of Common Stock and pay cash to
the Purchaser in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common
Stock, multiplied by (B) the Closing Bid Price on the Deadline Date. A Purchaser shall provide the Company with written notice
indicating the amounts payable to such Purchaser in respect of the Buy-In, together with applicable confirmations and other evidence
reasonably requested by the Company.

  

    	23

    	 

    

 

4.2.          Furnishing
of Information. In order to enable the Purchasers to sell the Shares under Rule 144, until the date that the Shares cease to
be Registrable Securities (as defined in the Registration Rights Agreement) (and for no less than 12 months from the Closing),
the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within
the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.
If the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and
make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Shares
under Rule 144.

 

4.3.          No
Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2
of the Securities Act) that will be integrated with the offer or sale of the Shares in a manner that would require the registration
under the Securities Act of the sale of the Shares to the Purchasers, or that will be integrated with the offer or sale of the
Shares for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to
the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

 

4.4.          Securities
Laws Disclosure; Publicity. On or before 9:00 a.m., New York City time, on the Business Day immediately following the date
hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable to the Placement
Agent disclosing all material terms of the transactions contemplated hereby. On or before 5:30 p.m., New York City time, on the
fourth Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with
the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K
the material Transaction Documents (including, without limitation, this Agreement and the Registration Rights Agreement)). Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser or an Affiliate of any Purchaser, or include the
name of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission (other than the Registration
Statement) or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as
required by federal securities laws in connection with (i) any registration statement contemplated by the Registration Rights
Agreement or (ii) the filing of final Transaction Documents (including signature pages thereto) with the Commission, and (b) to
the extent such disclosure is required by law, upon request of the staff of the Commission or Trading Market regulations, in which
case the Company shall provide the Purchasers with prior written notice of such disclosure permitted under this subclause (b).
From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received
from the Company or any of its officers, directors, employees or agents, that is not disclosed in the Press Release. Each Purchaser,
severally and not jointly with the other Purchasers, covenants that it will comply with the provisions of any confidentiality or
nondisclosure agreement executed by it and, in addition, until such time as the transactions contemplated by this Agreement are
required to be publicly disclosed by the Company as described in this Section 4.4, such Purchaser will maintain the
confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).

 

    	24

    	 

    

 

4.5.          Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that neither
it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information regarding
the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser,
unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information.
The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in
securities of the Company.

 

4.6.          Use
of Proceeds. The Company shall use the net proceeds from the sale of the Shares hereunder for working capital and general corporate
purposes.

 

4.7.          Indemnification
of Purchasers. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements
made by the Company in this Agreement or in the other Transaction Documents (provided that, the Company will not be liable
to any Purchaser Party under this Agreement to the extent, but only to the extent, that the loss is attributable to any Purchaser
Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement
or in any of the other Transaction Documents). Promptly after receipt by any such Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to this Section 4.7, such Indemnified Person
shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel
reasonably satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses relating to such action,
proceeding or investigation; provided, however, that the failure of any Indemnified Person to so notify the Company
shall not relieve the Company of its obligations hereunder except to the extent that the Company is actually and materially prejudiced
by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified
Person shall have mutually agreed to the retention of such counsel; (ii) the Company shall have failed promptly to assume
the defense of such proceeding and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or
(iii) in the reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company shall not be liable for any settlement
of any proceeding effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned.
Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned,
the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person
is or could have been a party and indemnity could have been sought hereunder by such Indemnified Person, unless such settlement
includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding.

 

    	25

    	 

    

 

4.8.          Form
D; Blue Sky. The Company agrees to timely file a Form D with respect to the Shares as required under Regulation D and to provide
a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Shares for
sale to the Purchasers at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of
the states of the United States (or to obtain an exemption from such qualification) and shall provide evidence of such actions
promptly upon the written request of any Purchaser.

 

4.9.          Subsequent
Equity Sales. From the date hereof until 30 days after the Effective Date of the Initial Registration Statement (as defined
in the Registration Rights Agreement), the Company shall not issue shares of Common Stock or Common Stock Equivalents; provided, however,
that the 30-day period set forth in this Section 4.9 shall be extended for the number of Trading Days during such
period in which (a) trading in the Common Stock is suspended by any Trading Market, or (b) following the Effective Date
of the Initial Registration Statement, the Registration Statement is not effective or the prospectus included in the Registration
Statement may not be used by the Purchasers for the resale of the Shares. Notwithstanding the foregoing, in no event shall this Section
4.9 prohibit the Company from issuing shares of Common Stock or Common Stock Equivalents (i) in connection with acquisitions
or strategic transactions (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual
property license agreements) approved by a majority of the disinterested directors of the Company; provided, that
any such issuance shall only be to a Person which is, itself or through its Subsidiaries, an operating company in a business synergistic
with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not
include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities, or (ii) upon the exercise of any options, warrants or other convertible securities
outstanding on the date hereof; provided, that the terms and the conditions of the Shares are not amended after
the date hereof in connection with any such issuance, or (iii) to employees, directors or consultants pursuant to any stock
option, equity incentive or employee stock purchase plan approved by a majority of the disinterested directors of the Company.

 

    	26

    	 

    

 

ARTICLE V

CONDITIONS PRECEDENT TO CLOSING

 

5.1.          Conditions
Precedent to the Obligations of the Purchasers to Purchase Shares. The obligation of each Purchaser to acquire Shares at the
Closing is subject to the fulfillment, on or prior to the Closing Date, of each of the following conditions, any of which may be
waived by such Purchaser (as to itself only):

 

(a)          Representations
and Warranties. The representations and warranties of the Company contained in Section 3.1 shall be true and
correct in all material respects (other than representations and warranties which are already qualified as to materiality, which
shall be true and correct in all respects) as of the date when made and as of the Closing Date, as though made on and as of such
date, except for such representations and warranties that speak as of a specific date, which shall be true and correct as of such
specified date.

 

(b)          Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

(d)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Shares at the Closing, all of which shall be and remain so long as necessary in
full force and effect.

 

(e)          Adverse
Change. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had or would
reasonably be expected to have a Material Adverse Effect.

 

(f)          No
Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission
or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal
Trading Market have been threatened, as of the Closing Date, either (i) in writing by the Commission or the Principal Trading
Market or (ii) by falling below the minimum listing maintenance requirements of the Principal Trading Market.

 

    	27

    	 

    

 

(g)          Company
Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).

 

(h)          Compliance
Certificate. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed by its
Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified in Sections
5.1(a) and (b) in the form attached hereto as Exhibit F.

 

5.2.          Conditions
Precedent to the Obligations of the Company to Sell Shares. The Company’s obligation to sell and issue the Shares at
the Closing to the Purchasers is subject to the fulfillment, on or prior to the Closing Date, of the following conditions, any
of which may be waived by the Company:

 

(a)          Representations
and Warranties. The representations and warranties made by the Purchasers in Section 3.2 shall be true and
correct in all material respects (other than representations and warranties which are already qualified as to materiality, which
shall be true and correct in all respects) as of the date when made, and as of the Closing Date as though made on and as of such
date, except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specified
date.

 

(b)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

(c)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Shares at the Closing, all of which shall be and remain so long as necessary in
full force and effect.

 

(d)          Performance.
Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing
Date.

 

(e)          Purchaser
Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).

 

    	28

    	 

    

 

ARTICLE VI

MISCELLANEOUS

 

6.1.          Fees
and Expenses. Except as otherwise expressly set forth in the Company’s engagement letter with the Placement Agent, the
Company and each Purchaser, severally and not jointly with any other Purchaser, shall pay the fees and expenses of their respective
advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection with the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees,
stamp taxes and other taxes and duties levied in connection with the sale and issuance of the Shares to the Purchasers. Each Purchaser,
severally and not jointly with any other Purchaser, shall be responsible for all other tax liability that may arise as a result
of the holding or transferring of the Shares by it.

 

6.2.          Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver
to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties
under the Transaction Documents.

 

6.3.          Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number
specified in this Section 6.3 prior to 5:00 p.m., New York City time, on a Trading Day, (b) the next Trading
Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified
in this Section 6.3 on a day that is not a Trading Day or later than 5:00 p.m., New York City time, on any Trading
Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with
next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as follows:

 

If to the Company:             Capricor
Therapeutics, Inc.

8840 Wilshire Blvd., 2nd Floor

Beverly Hills, CA 90211

Telephone No.: (310) 358-3200

Facsimile No.: (310) 358-3209

Attention: General Counsel

 

With a copy to (which shall not
constitute notice):

 

Paul Hastings LLP

1117 S. California Avenue

Palo Alto, California 94304

Telephone No.: (650) 320-1830

Facsimile No.: (650) 320-1930

Attention: Rob R. Carlson, Esq.

 

    	29

    	 

    

 

If to a Purchaser:         To
the address set forth under such Purchaser’s name on the signature page hereof;

 

or such other address as may be designated
in writing hereafter, in the same manner, by such Person.

 

6.4.          Amendments;
Waivers; No Additional Consideration. No provision of this Agreement may be waived, modified, supplemented or amended except
in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire
66 2/3% of the Shares at the time of such amendment (which amendment shall be binding on all Purchasers) or, in the case of a waiver,
by the party against whom enforcement of any such waiver is sought; provided, that any amendment, waiver, modification
or supplement of this Agreement that modifies the Subscription Amount of any Purchaser, the Purchase Price or Section 2.1(a), Section
2.1(c), Section 2.2, Section 3.1(y), Section 4.4 or this Section 6.4 of
this Agreement or causes any such Purchaser to assume any additional liability or material obligation, may be effected only pursuant
to a written instrument signed by the Company and such Purchaser. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise
any right hereunder in any manner impair the exercise of any such right. No consideration shall be offered or paid to any Purchaser
to amend or consent to a waiver or modification of any provision of any Transaction Document unless the same consideration is also
offered to all Purchasers who then hold Shares.

 

6.5.          Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement,
unless the context clearly indicates to the contrary. The language used in this Agreement will be deemed to be the language chosen
by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement
shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents.

 

6.6.          Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors
and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the written
consent of Purchasers holding or having the right to acquire 66 2/3% of the Shares at the time of such consent. Any Purchaser may
assign its rights hereunder in whole or in part to any Person to whom such Purchaser assigns or transfers any Shares in compliance
with the Transaction Documents and applicable law, provided that such transferee shall agree in writing to be bound, with respect
to the transferred Shares, by the terms and conditions of this Agreement and the Registration Rights Agreement that apply to the
“Purchasers” by executing a joinder agreement to each of the same.

 

    	30

    	 

    

 

6.7.          No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except (i) the
Placement Agent is an intended third party beneficiary of Article III hereof and (ii) each Purchaser Party is an intended
third party beneficiary of Section 4.7.

 

6.8.          Governing
Law. This Agreement and the relationship of the parties to this Agreement shall be construed in accordance with, and governed
in all respects by, the internal laws of the State of New York (without giving effect to principles of conflicts of laws). Each
party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this
Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates, employees or
agents) shall be commenced exclusively in any state or federal court located in the County of Los Angeles, State of California.
Each party hereto hereby irrevocably submits to the exclusive jurisdiction of each state and federal court located in the State
of California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives,
and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such County
of Los Angeles, State of California court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each
party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY.

 

6.9.          Survival.
Unless this Agreement is terminated in accordance with Section 6.17, the representations, warranties, agreements and
covenants contained herein shall survive the Closing and the delivery of the Shares, subject in each case to the applicable statute
of limitations.

 

6.10.         Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page
were an original thereof.

 

    	31

    	 

    

 

6.11.         Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.

 

6.12.         Replacement
of Shares. If any instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause
to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new instrument,
but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer Agent of such loss, theft or destruction
and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and
hold harmless the Company and the Transfer Agent for any losses in connection therewith or, if required by the Transfer Agent,
a bond in such form and amount as is required by the Transfer Agent. The applicants for a new instrument under such circumstances
shall also pay any reasonable third-party costs associated with the issuance of such replacement Shares. If a replacement instrument
evidencing any Shares is requested due to a mutilation thereof, the Company may require delivery of such mutilated instrument as
a condition precedent to any issuance of a replacement.

 

6.13.         Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the
foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection
with any action for a temporary restraining order) the defense that a remedy at law would be adequate.

 

6.14.         Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.15.         Adjustments
in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing,
each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately
account for such event.

 

    	32

    	 

    

 

6.16.         Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Shares pursuant
to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information,
materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations,
condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other
Purchaser or by any agent or employee of any other Purchaser, and no Purchaser nor any of its agents or employees shall have any
liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials, statement or
opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall
be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create
a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser
in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection
with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled
to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of
the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any
proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for
the convenience of the Company and not because it was required or requested to do so by any Purchaser.

 

6.17.         Termination.
This Agreement may be terminated and the sale and purchase of the Shares abandoned at any time prior to the Closing by either the
Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been consummated
on or prior to 5:00 p.m., New York City time, on the Outside Date; provided, however, that the right to
terminate this Agreement under this Section 6.17 shall not be available to any Person whose failure to comply with
its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such
time. Nothing in this Section 6.17 shall be deemed to release any party from any liability for any breach by such
party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel
specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. In the event
of a termination pursuant to this Section 6.17, the Company shall promptly notify all non-terminating Purchasers. Upon
a termination in accordance with this Section 6.17, the Company and the terminating Purchaser(s) shall not have any
further obligation or liability (including arising from such termination) to the other, and no Purchaser will have any liability
to any other Purchaser under the Transaction Documents as a result therefrom. The Company and any Purchaser(s) may extend the term
of this Agreement in accordance with the amendment provisions of Section 6.4.

 

    	33

    	 

    

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	34

    	 

    

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Share
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

	 	COMPANY
	 	 
	 	Capricor Therapeutics, Inc.,
	 	a Delaware corporation
	 	 	 
	 	By:	 
	 	Name: 	Linda Marbán, Ph.D.
	 	Title: 	Chief Executive Officer

 

[SIGNATURE PAGES OF
PURCHASERS FOLLOW]

 

    	35

    	 

    

  

	NAME OF PURCHASER:
	 
	Signature:	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

  

	Aggregate Purchase Price (Subscription Amount): 
	$	 	 
	 
	Number of Shares to be Acquired: ______________

 

	Tax ID No.:	 	 
	 	 	 
	Address for Notice/Residency of Purchaser:
	 	 
	c/o	 	 
	Street:	 	 
	City/State/Zip:	 	 
	Attention:	 	 
	Telephone No.:	 	 
	Facsimile No.:	 	 
	E-mail Address:	 	 

 

	Delivery Instructions:	 
	(if different than above)	 
	 	 	 
	c/o	 	 
	Street:	 	 
	City/State/Zip:	 	 
	Attention:	 	 
	Telephone No.:	 	 

 

[SIGNATURE PAGES CONTINUE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]